Home / Health / Novavax RSV vaccine fails advanced study; stocks down 63% before marketing – Seeking Alpha

Novavax RSV vaccine fails advanced study; stocks down 63% before marketing – Seeking Alpha




Novavax RSV vaccine fails advanced study; shares down 63% before marketing

Novavax (NVAX) is ready for significant pre-market marketing, following the results of a Phase 3 clinical trial, Prepare, evaluating ResVax, an alumin.

View full coverage on Google News
Source link